作为改变人类生命质量与发展进程的一种工具,生物芯片——其中高密度基因芯片是最重要的一种生物芯片——产业无疑将是21世纪的朝阳产业。美国已投资数十亿美元用于基因芯片的开发,国际上许多著名的大公司也都投入巨资研制,但目前世界上获得成功的还只是实验室阶段的产品,还没有一枚用于临床诊断的基因芯片投产。令人振奋的是:最近,由广东羊城晚报报业集团属下投资,留学归国的马文丽博士和郑文岭博士采用独创的技术自行研制的中国第一 As a tool to change the quality of human life and the development process, bio-chips - of which high-density microarray is the most important biochip - will undoubtedly be the sunrise industry in the 21st century. The United States has invested billions of dollars for the development of gene chips. Many well-known large companies in the world have also invested heavily in research and development. However, the world has only succeeded in the laboratory phase of the product, but not yet used in clinical Diagnostic gene chip production. What is exciting is: Recently, Ma Bingli and Dr. Zheng Wenling who have invested in Guangdong Yangcheng Evening News Press Group and returned from abroad have adopted the original technology developed by China first